CONTACT US
Back to Resources
Back to Resources

Why Precision Oncology Access is Determined Upstream

precision-oncology-access

In precision oncology, the gap between a breakthrough therapy and the patient who needs it is rarely scientific – it's operational. 

This white paper unpacks findings from our OncoGenius® 2026 Biomarker Report, a survey of 72 leading U.S. cancer centers and community practices, that reveals how provider operations, biomarker testing workflows, and payer policies are shaping access to targeted therapies. 

With more than 120 biomarker-defined cancer therapies now in clinical use, the science has never been stronger, but inconsistent testing protocols and fragmented EHR workflows mean that eligible patients are still missing out on treatments.

Download this preview to see where the system is falling short and what manufacturers can do to close the gap before treatment decisions are ever made.

For the full dataset and analysis, connect with our team about OncoGenius.

Author: Shraddah Kansagra, PharmD, BCOP

Download Now
oncology-access-determined-upstream

What you'll learn:

  • The true cost of testing delays: How gaps in biomarker testing turnaround time affect when patients start treatment and whether they receive the therapy best suited to their molecular profile
  • How payer policies are shaping access upstream: Where prior authorization, coverage inconsistencies, and denial patterns are creating barriers long before a prescription is written
  • What manufacturers can do to drive change: Practical strategies for engaging earlier in the testing pathway to improve patient identification, standardize ordering, and turn regulatory approval into real-world access

Why Precision Oncology Access is Determined Upstream